Thomas D. Stuckey, MD, FACC, FSCAI

Advantage: Tirofiban in the Complex Puzzle of ACS Pharmacotherapeutics

09/07/2015

High-dose bolus tirofiban has been an excellent, cost-effective way to deal with patients who do not have optimal platelet inhibition at the time of PCI. It’s given us the flexibility to deal with that unmet need.

High-dose bolus tirofiban has...

09/07/2015

Cath Lab Digest

Original Contribution

Outcomes After Successful Percutaneous Coronary Intervention of Calcified Lesions Using Rotational Atherectomy, Cutting-Balloon Angioplasty, or Balloon-Only Angioplasty Before Drug-Eluting Stent Implantation

06/15/2017

Bjorn Redfors , MD, PhD;

Bernhard Witzenbichler , MD;

Thomas D. Stuckey , MD, FACC, FSCAI;

Roxana Mehran , MD;

Thomas C. McAndrew , PhD, MS;

Giora Weisz , MD;

Gregg W. Stone , MD, FACC, FSCAI;

Philippe Généreux , MD;

Ajay J. Kirtane , MD, SM;

Akiko Maehara , MD;

Timothy D. Henry , MD;

We report the adverse event rates after rotational atherectomy (RA) with contemporary drug-eluting stent implantation and compare RA to cutting balloon angioplasty and balloon-only angioplasty in the all-comers ADAPT-DES trial.

We report the adverse event...

06/15/2017

Journal of Invasive Cardiology